FDA Clears New Blood Test for Alzheimer’s Diagnosis

The Food and Drug Administration (FDA) has cleared a new blood test developed to assist in diagnosing Alzheimer’s disease. This test, known as PrecivityAD2, was created by C2N Diagnostics. It targets adults over 40 who show signs of cognitive impairment.

The test is intended for use alongside clinical evaluations. It helps healthcare professionals identify Alzheimer’s but is not designed as a standalone or screening tool. It marks the first approval by the FDA for such a test in symptomatic adults aged 40 and over, as confirmed by C2N Diagnostics.

Alzheimer’s is the most prevalent form of dementia, responsible for 60 to 80 percent of cases, according to the Alzheimer’s Association. Approximately 7.4 million Americans over 65 are affected, and predictions suggest this number may rise to 13.8 million by 2060.

Current Detection Methods for Alzheimer’s

Alzheimer’s is characterized by the accumulation of two proteins, beta-amyloid and tau, which damage nerve cells. This damage results in symptoms like memory loss, personality changes, and challenges in daily tasks. Diagnosis involves reviewing symptoms and obtaining input from family members. Key symptoms include memory issues, difficulty concentrating, poor decision-making, mood changes, and confusion.

Based on symptoms, clinicians may use laboratory tests and brain imaging to confirm the diagnosis.

Functionality of the New Blood Test

The new blood test by C2N Diagnostics detects amyloid plaques associated with Alzheimer’s, supporting clinical assessments. In a validation study, it showed a positive predictive value of 97.6 percent and a negative predictive value of 93.1 percent.

The test effectively detects amyloid plaques across various levels of cognitive impairment. Dr. Joel Braunstein, C2N Co-Founder and CEO, highlighted the FDA clearance as pivotal for Alzheimer’s diagnostics and precision medicine. He stated it simplifies diagnostic processes for patients with serious memory issues.

Implications for Alzheimer’s Diagnosis

The blood test offers diagnostic insights without needing a PET scan, streamlining the evaluation process. Research indicates that using multiple biomarker tests can expedite the initiation of amyloid targeting treatments. Thus, the blood test can potentially enable faster diagnosis and treatment for patients, enhancing healthcare outcomes.